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ABSTRACT 
Objective: The objective of our investigation was to formulate a liquid self micro emulsifying drug delivery system (SMEDDS) of candesartan 
cilexetil that could improve its solubility, stability, and oral bioavailability. 
Methods: The prepared SMEDDS was the concentrate of drug, oil, surfactant, cosurfactant. The formulation was evaluated for various tests like 
solubility, Drug-surfactant compatibility, particle size, zeta potential, in vitro dissolution, etc. 
Results: The optimized formulation C7IIB showed drug release (99.91%), droplet size (9.15 nm), Zeta potential (-23.2), viscosity (0. 8824 cP) and 
infinite dilution capability. In vitro drug release of the C7IIB was highly significant (p<0.05) as compared to marketed conventional tablet (M).  
Conclusion: The present investigation shows that candesartan cilexetil Self microemulsifying drug delivery system can be formulated as unit 
dosage form. The C7IIB can be further used for the preparation of various Solid SMEDDS(S-SMEDDS) formulations. 
Keywords: Self microemulsifying drug delivery system, Candesartan cilexetil, Drug release, Stability study, Bioavailability 
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INTRODUCTION 
Candesartan cilexetil is an esterified prodrug of candesartan, a 
nonpeptide angiotensin II type 1(AT1) receptor antagonist used in 
the treatment of hypertension. Based on its solubility across 
physiological relevant pH conditions and absorption characteristic, 
candesartan cilexetil is classified in the Biopharmaceutical 
classification system as a class II dug. Low solubility of candesartan 
cilexetil across the physiological pH range is reported to result in 
incomplete absorption from the GI tract and hence is reported to 
have an oral bioavailability of about 15%. candesartan cilexetil is a 
highly lipophilic compound and has good solubility in tri and 
diglyceride oils. 
Thus,a novel oral formulation of candesartan cilexetil can be 
developed which increases its solubility and enhances permeability 
across the biological membrane to overcome its poor bioavailability.  
Lipid-based formulation approaches, particularly the self-
microemulsifying drug delivery system (SMEDDS), are well known 
for their potential as alternative strategies for delivery of 
hydrophobic drugs [1], which are associated with poor water 
solubility and low oral bioavailability[2, 3]. SMEDDS formulations 
are isotropic mixtures of an oil, a surfactant, a co surfactant (or 
solubilizer), and a drug. The basic principle of this system is its 
ability to form fine oil-in-water (o/w) microemulsions under gentle 
agitation following dilution by aqueous phases (i.e., the digestive 
motility of the stomach and intestine provide the agitation required 
for self-emulsification in vivo in the lumen of the gut)[4].  
This spontaneous formation of an emulsion in the gastrointestinal 
tract presents the drug in a solubilized form, and the small size of the 
formed droplet provides a large interfacial surface area for drug 
absorption [5]. Apart from solubilization, the presence of lipid in the 
formulation further helps improve bioavailability by affecting the drug 
absorption [1]. Selection of a suitable self-emulsifying formulation 
depends upon the assessment of (i) the solubility of the drug in 
various components, (ii) the area of the self-emulsifying region as 
obtained in the phase diagram, and (iii) the droplet size distribution of 
the resultant emulsion following self-emulsification [6]. 
The objective of this study was to develop and characterize liquid 
SMEDDS of candesartan cilexetil for increasing solubility and 
permeability across the biological membrane to improve the 
bioavailability, dosing frequency, in vitro dissolution as well as 
enhance patient compliance.  
MATERIALS AND METHODS 
Materials for component selection 
Candesartan cilexetil was obtained as a gift sample from Alembic 
Pharma Ltd, Baroda, Gujarat. Transcutol P, Capryol 90, Plurol Oleique, 
Labrasol, Labrafil 1944 CS, Peceol were obtained as a gift sample from 
Gattefosse, France. Captex 500, Capmul MCM (C8), Captex 200, Captex 
200 P, Captex 355 were kindly gifted by Abitec Corporation, Janesville, 
USA. Polyethylene Glycol 400 was purchased from Suvidhinath 
Chemicals. The other chemicals used were of the analytical grades. 
Double-distilled water was used throughout the study. 
Screening of components 
The most important criterion for the screening of components for 
SMEDDS is the solubility of poorly soluble drug in oils, surfactants 
and co-surfactants. Since the aim of this study is to develop an oral 
formulation, therefore, solubility of drug in oils is more important as 
the ability of SMEDDS to maintain the drug in solubilized form is 
greatly influenced by the solubility of the drug in oil phase. In this 
study excess amount of drug was added to 2 ml of each vehicle 
separately in screw capped glass vial and mixture was heated to 60 °C 
in water bath under continuous stirring using a vortex mixture to 
facilitate drug solubilization. The vials were then kept at 25±1.0 °C in 
an isothermal shaker for 72 h to reach equilibrium. The equilibrated 
samples were removed from shaker and centrifuged at 2000 rpm for 
10 min. The supernatant was taken, filtered and diluted with 
methanol. The concentration of candesartan cilexetil was determined 
for various vehicles using HPLC technique [13, 14, 16]. 
Preparation of candesartan cilexetil SMEDDS 
A series of SMEDDS formulations were prepared using various oils, 
Surfactants and Co-surfactants as shown in table 1. In all the 
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formulations, the level of Candesartan cilexetil was kept constant 
(i.e. 32 mg). The amount of oil should be such that it should 
solubilize the drug (single dose) completely. Candesartan cilexetil 
was added in the oil phase and solubilized. Then the mixture of 
surfactant and co-surfactant (Smix) was added in the oil phase, 
mixed by gentle stirring, vortex mixing and heating at 37±0.5 °C. The 
mixture was stored at room temperature until used. Thus, the 
prepared SMEDDS was the concentrate of oil, surfactant, 
cosurfactant and drug. Total 96 liquid formulations were prepared 
using various surfactants and cosurfactant concentrations. 
 
Table 1(a): Various formulations of candesartan cilexetil SMEDDS 
Ingredients C1 C2 C3 C4 C5 C6 C7 C8 
Candesartan cilexetil √ √ √ √ √ √ √ √ 
Capryol 90 √ √ √ √ √ √ √ √ 
Labrasol    √ √  √ √ 
Peceol √        
Plurol Oleique √        
Transcutol P  √ √      
Tween 80      √   
Lauroglycol  √ √      
Capmul MCM (C8)    √     
Capmul MCM (EP)     √    
Acconon cc-6      √  √ 
Captex 500       √  
 
Table 1(b): Various concentrations of oil and S/CoS 
Code Amount of oil (%) Code Ratio of S/CoS 
I 5 A 1:1 
II 10 B 2:1 
III 15 C 1:2 
  D 3:1 
 
Drug and surfactant compatibility study 
Physical compatibility of the water-insoluble drug with surfactants 
should be used in surfactant selection procedure. Physical 
compatibility may include precipitation/crystallization, phase 
separation and color change in the drug–surfactant solution during 
course study. Chemical compatibility is primarily regarded as the 
chemical stability of the drug in a surfactant solution. A surfactant 
was considered for further development only if it was physically and 
chemically compatible with drug [15]. 
Pseudoternary phase diagram 
The existence of microemulsions regions was determined by using 
pseudo-ternary phase diagrams. SMEDDS were diluted under agitation 
conditions using water titration method [17]. The mixture of oil and 
Smix at certain weight ratios were diluted with water in a dropwise 
manner. Phase diagrams were constructed in the presence of drug to 
obtain the optimum concentrations of oil, surfactant and co-surfactant. 
SMEDDS form fine oil-water emulsion upon addition to an aqueous 
media under gentle agitation. Distill water was used as an aqueous phase 
for the construction of phase diagrams. As the free energy required for 
forming an emulsion is very low, the formation is thermodynamically 
spontaneous. The surfactants used in formulation form a layer around 
the emulsion droplets thus reducing the interfacial energy and providing 
a mechanical barrier. The spontaneity was measured by visual 
observations. The concentration of water at which turbidity-to-
transparency and transparency-to-turbidity transitions occurred was 
derived from the weight measurements. These values were then used to 
determine the boundaries of the microemulsion domain corresponding 
to the chosen value of oils, as well as the Smix ratio [17]. 
Thermodynamic stability 
Heating cooling cycle 
Six cycles between refrigerator temperature 4 °C and 45 °C with 
storage at each temperature of not less than 48hr was studied. 
Those formulations, which were stable at these temperatures, were 
subjected to centrifugation test. 
Centrifugation 
Passed formulations were centrifuged at 3500 rpm for 30 min. 
Those formulations that did not show any phase separation were 
taken for the freeze-thaw stress test. 
Freeze-thaw cycle 
Three freeze-thaw cycles between-21 °C and+25 °C with storage at 
each temperature for not less than 48hr was done for the 
formulations. Those formulations, which passed these thermodynamic 
stress tests, were further taken for the dispersibility test for assessing 
the efficiency of self-emulsification. The formulations were observed 
visually for any phase separation or color change. 
Dispersibility test 
The efficiency of self -emulsification of oral SMEDDS was assessed 
using a standard USP XXII dissolution apparatus 2[18]. 1 ml of each 
formulation was added to 500 ml of water at 37±0.5 °C. A standard 
stainless steel dissolution paddle rotating at 50 rpm provided gentle 
agitation. The in vitro performance of the formulations was visually 
assessed using the following grading system:  
Grade A: Rapidly forming (within 1 min) microemulsion, having a 
clear or bluish appearance. 
Grade B: Rapidly forming, slightly less clear microemulsion, having a 
bluish-white appearance. 
Grade C: Fine milky microemulsion that formed within 2 min. 
Characterization of smedds of candesartan cilexetil 
Viscosity and pH 
The viscosities were measured to determine rheological properties 
of formulations. Brookfield LVDV 111+CP viscometer at 30 °C with a 
CPE 42 spindle at 5 rpm was used to serve this purpose. The pH of 
the formulations was measured using pH meter.  
Globule size and ζ-potential analysis 
One gram of SMEDDS was dispersed in 100 ml distilled water and 
0.1 mol/l HCl, at 37±0.5 °C. The resultant emulsions were prepared 
by gentle agitation for 10 min using a magnetic stirrer. The globule 
size and ζ-potential of the resulting microemulsions was determined 
using Malvern zeta sizer. 
% Transmittance 
The % transmittance of various formulations was measured at 254 
nm using UV spectrophotometer keeping methanol as a blank.  
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The procedure for preparation of the sample is same as for globule 
size and zeta potential. The poly dispersibility index is measured 
using the Malvern zeta sizer. 
In vitro diffusion study 
In vitro drug diffusion study was carried out by using dialysis bag 
method. Dialysis bag was soaked overnight in 0.1 N HCl for saturation 
purpose and then it was further used for experimental procedure.1 ml of 
candesartan cilexetil SMEDDS diluted with aqueous phase was instilled 
in dialysis bag and one end was tied with thread and was placed in 900 
ml of 0.02% Tween 20 in 0.1 N HCl as dissolution medium at 37±0.5 °C 
temperature. The revolution speed of paddle was maintained at a rate of 
50 rpm [19]. An aliquot of 5 ml was withdrawn at regular time intervals 
of 0, 5, 10, 20, 30, 45 and 60 min. The SMEDDS formulation was 
compared with the conventional marketed tablet formulation (Atacand 
32 mg tablet) and the suspension of pure drug. The samples were 
analyzed for the drug content using HPLC method at 254 nm.  
RESULTS AND DISCUSSION 
Screening of components 
One important consideration when formulating a self-micro 
emulsifying formulation is avoiding precipitation of the drug on 
dilution in the gut lumen in vivo. Therefore, the components used in 
the system should have high solubilization capacity for the drug, 
ensuring the solubilization of the drug in the resultant dispersion. 
Results from solubility studies are reported in table 2. The solubility 
of candesartan cilexetil was found to be highest in Capryol 90 
(80.12±4.04 mg/ml) as compared to other oils while in water it was 
0.09±0.01 mg/ml. This may be attributed to the polarity of the 
poorly water soluble drugs that favor their solubilization in 
small/medium molecular volume oils such as medium chain 
triglycerides or mono-or diglycerides [30]. Thus, Capryol 90 was 
selected as the oil phase for the development of the formulation. 
Table 2: Solubility study of candesartan cilexetil in various vehicles 
(oils, surfactants, Co surfactants and distill water) at 25 °C 
Solvent Solubility 
Transcutol P 253.1±0.27 
Plurol oleique 169.21±2.19 
Labrasol 159.7±3.53 
Capryol 90 80.12±4.04 
Labrafil 1944 CS 49.76±1.13 
Captex 200 5.67±0.68 
Captex 200 P 7.29±0.94 
Captex 355 10.31±1.02 
Capmul MCM 35.02±1.32 
Tween 80 261.09±2.85 
PEG 400 108.13±3.22 
IPM 22.54±0.29 
Lauroglycol FCC 177.05±1.54 
Capmul MCM (C8) 198.70±2.13 
Acconon CC-6 181±1.76 
Captex 500 191.35±2.78 
Capmul MCM EP 173.64±1.19 
Distill water 0.09±0.01 
 *mean±SD, n=3 
 
Drug and surfactant compatibility study 
Physical and chemical compatibility of the water-insoluble drug 
candesartan cilexetil with various surfactants and co-surfactants 
was carried out to check the physical as well as chemical 
compatibility. As shown in table 3, all the formulations passed the 
physical as well as chemical compatibility tests. The formulations 
did not show any changes during the compatibility studies and were 
found to be stable. Further studies were carried out using these 
formulations [30]. 
 
Table 3: Drug surfactant compatibility study 
Formulation Precipitation Crystallization Phase separation Color change 
C1 √ √ √ √ 
C 2 √ √ √ √ 
C 3 √ √ √ √ 
C 4 √ √ √ √ 
C 5 √ √ √ √ 
C6 √ √ √ √ 
C7 √ √ √ √ 
C8 √ √ √ √ 
 Where, √-Passed and ×-Failed  
 
Pseudoternary phase diagram 
Self-micro emulsifying systems from fine oil-water emulsions with only 
gentle agitation, upon their introduction into aqueous media. Surfactant 
and co-surfactant get preferentially adsorbed at the interface, reducing 
the interfacial energy as well as providing a mechanical barrier to 
coalescence. The decrease in the free energy required for the emulsion 
formation consequently improves the thermodynamic stability of the 
microemulsion formulation [9, 10]. Therefore, the selection of oil and 
surfactant, and the mixing ratio of oil to S/CoS, play an important role in 
the formation of the microemulsion. 
In the present study capryol 90 was tested for phase behavior 
studies with labrasol and Captex 500 as the S/CoS mixture. As seen 
from the ternary plot C7IIB gave a wider microemulsion region at all 
S/CoS ratios. The microemulsion area increased as the S/Cos ratios 
increased. However, it was observed that increasing the surfactant 
ratio resulted in a loss of flowability. Thus, an S/CoS ratio 10% 2:1 
was selected for the formulation study.  
Viscosity and pH 
The viscosity of microemulsion systems can be monitored by 
standard rheological techniques. All the formulation has a viscosity 
which is highly similar to that of water i.e.1.0. Thus, it shows that 
SMEDDS forms o/w microemulsion and water remains as external 
phase. The results of viscosity are as shown in table 4.  
The excipients used in the formulation decide the pH of the final 
preparation. The change in the pH may affect the zeta potential of 
the formulation which in turn can affect the stability of preparation. 
All the formulations showed similar pH values in the range of 5.1 to 
6.0. Thus, pH is not affecting stability. Therefore, it can be assumed 
that drug is not diffusing in the external phase and remains in the oil 
phase. Since water is the external phase entire system showed pH of 
water. Candesartan cilexetil is unstable in alkaline pH. Here the 
formulations show acidic to neutral pH which is suitable for the 
stability of Candesartan cilexetil. 
 
Table 4: Viscosity and pH of various SMEDDS formulations 
Formulation code Viscosity (cp) pH 
C 4III D 0.8865 5.12 
C7III D 0.8887 5.57 
C4 II B 0.8812 5.88 
C7 II B 0.8824 5.14 
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Fig. 1: Phase diagrams for various liquid SMEDDs formulations 
 
Dispersibility and thermodynamic stability 
In the present study, we used distilled water as a dispersion medium 
because it is well reported that there is no significant difference in 
the microemulsions prepared using nonionic surfactants, dispersed 
in either water or simulated gastric or intestinal fluid  [32]. Keeping 
the criteria of increasing oil concentration and minimum amount of 
surfactant used for its solubilization, one formulation for each 
percent of oil (5%, 10% and 15%) was selected irrespective of the 
Smix ratio used for that percent of oil. The results for the 
dispersibility test are as shown in table 5. 
SMEDDS are thermodynamically stable systems and are formed at a 
particular concentration of oil, surfactant and water, with no phase 
separation, creaming or cracking. Thus, the selected formulations 
were subjected to different thermodynamic stability by using 
heating-cooling cycle, centrifugation, and freeze-thaw cycle stress 
tests. Those formulations, which survived thermodynamic stability 
tests, were taken for dispersibility test. It was observed that 
formulation prepared from Capryol 90 as oil; Labrasol as surfactant 
whereas Captex 500 and Capmul MCM (C8) as co surfactant pass the 
thermodynamic stress tests and thus were used for further study. 
The results are as shown in table 5. 
 
Table 5: Thermodynamic stability and dispersibility test of different formulations 
Formulation code A B C D 
C2I Xx xx Xx Xx 
C2II Xx xx Xx + 
C2III Xx xx Xx + 
C4I + + X + 
C4II + + + + 
C4III + + + + 
C7I + + + + 
C7II + + + + 
C7III + + + + 
C8I + + + + 
C8II + + + + 
C8III + + + + 
Where; I-5%; II-10% and III-15% oil concentration. Also, Whitish-XX; Slightly whitish-X and clear-+is visual appearance. 
 
Globule size and ζ-potential analysis 
The globule size of the emulsion is a crucial factor in self-
emulsification performance because it determines the rate and 
extent of drug release as well as drug absorption. Also, it has been 
reported that the smaller globule size of the emulsion droplets may 
lead to more rapid absorption and improve the bioavailability [34]. 
Fig. 2 shows the particle size distribution of candesartan cilexetil 
SMEDDS diluted with water and 0.1 mol/l HCl, respectively. The 
optimal batch was C7IIB with mean globule size 9.15 nm in water.  
SMEDDS produced a resultant emulsion with a small mean globule 
size and a narrow globule size distribution regardless of the 
dispersion medium. The blank SMEDDS formulation exhibited 
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almost no charged emulsion whereas a negatively charged emulsion 
was obtained with drug-loaded SMEDDS. This may be because the 
emulsifier used in the formulation was a nonionic surfactant. The 
optimal batch C7IIB has the least zeta potential i.e.-23.2 mV which 
highest zeta potential towards the negative side. The zeta potential 
governs the stability of microemulsion; it is important to measure its 
value for the stability of samples. A negative force means a negative 
potential between the droplets. 
  
Table 6: Particle size and zeta potential of the optimized batch C7IIB of candesartan cilexetil SMEDDS 
Formulation code Avg. particle size (nm) Zeta potential 
Water HCL 




Fig. 2(a): Particle size of formulation C7IIB in 0.1 N HCL 
 
 
Fig. 2(b): Particle size of formulation C7IIB in water 
 
% Transmittance 
The clarity of microemulsions was checked by transparency, 
measured in terms of transmittance (%T). SMEDDS forms o/w 
microemulsion since water is an external phase. Formulation C7 has % 
transmittance value greater than 99%. These results indicate the high 
clarity of microemulsion. The results of %T are as shown in table 7. 
 
Table 7: % Transmittance for C7IIB formulation 
Period  (mo) %T 
25˚C 40˚C 
0 99.7±0.2 99.6±0.3 
1 99.6±0.5 99.4±0.2 
2 99.4±0.3 99.2±0.5 
3 99.3±0.6 95.4±0.7 
6 99.1±0.2 80.3±0.6 
 mean±SD, n=3 
 
Polydispersibility index (PDI) 
Polydispersibility, which determines size range of particles in the 
system, is measured by;  
No. of particles having size greater than 100 nm
No. of particles having size less than 100 nm
 ----------------- (1) 
It is expressed in terms of poly dispersibility index (PDI). An ideal 
SMEDDS should be widely distributed with particles less than 100 nm 
and so PDI should be less than 0.3 or in other words, particles having 
size more than 100 nm should be maximum up to 23%. The data are 
as shown in table 8. The results show that formulations C3ID and C3IB 
does not pass the test as they have PDI more than 0.3 whereas 
remaining all formulations pass the test as they have PDI less than 0.3. 
 
Table 8: Polydispersibility index of candesartan cilexetil 
SMEDDS formulations 
Formulation code PDI 
C4 II D 0.136 
C4II B 0.096 
C7 II D 0.246 
C7II B 0.221 
 
 
Fig. 3(a): In vitro diffusion study of various SMEDDS formulation 
 
In vitro diffusion study 
Sink conditions are often violated when using conventional release 
methods for dispersed systems. So, methods must be developed for 
SMEDDS to separate the dissolved drugs from micro emulsion-
associated drugs before their determination. It has been reported 
that a dialysis method and an ultrafiltration method have been 
applied to candesartan SMEDDS, and a relatively high release rate 
was obtained using the latter. In this study, a bulk-equilibrium 
reverse dialysis bag method was developed to allow an increase in 
the membrane surface area available for transport from the donor to 
the receiver phases and, hence, to maintain sink conditions in the 
donor phase by infinite dilution of the emulsion in the outer vessel.  
In the dissolution media, 0.02% of tween 20 was added since it 
provided better discrimation between the formulations. The faster 
dissolution from SMEDDS may be attributed to the fact that in this 
formulation, the drug is a solubilized form and upon exposure to 
dissolution medium results in small droplets that can dissolve 
rapidly in the dissolution medium.  
The dissolution profile for formulations C2II B, C4II B, C7II B and 
C8II B is as shown in the fig. 3. The formulation C7IIB showed 
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highest release rate among all the liquid SMEDDS formulations i.e. 
92.01% in 10 min which is highest among all batches. In this case, the 
drug was present in the form of micro globules of microemulsion and 
water was an aqueous phase. Due to low size of microemulsion 
particles, they easily diffuse through the dialysis membrane [19]. The 
results indicate that candesartan cilexetil SMEDDS can be diluted 
previously with aqueous phase before performing the in vitro release 
test in dialysis bag. Thus, in vitro study concludes that release of 
candesartan cilexetil was greatly enhanced by SMEDDS formulation. 
The batch C7IIB was thus taken for further studies and comparison. 
 
 
Fig. 3(b): In vitro diffusion study of C7IIB and M 
 
CONCLUSION 
A SMEDDS formulation of a poorly water soluble drug, candesartan 
cilexetil was formulated for oral administration. The formulation 
C7IIB was found to be the optimized formulation on the base of 
results of pseudo ternary phase diagram, in vitro drug release, 
droplet size and zeta potential. The optimized formulation showed 
rapid self-emulsification in aqueous media. In vitro drug release of 
the C7IIB was highly significant (p<0.05) as compared to 
conventional marketed tablet (M). The results from the study show 
the utility of SMEDDS to enhance solubility and dissolution of 
sparingly soluble compounds like candesartan cilexetil. 
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